

**Inhibikase Therapeutics, Inc.**  
3350 Riverwood Parkway, Suite 1900  
Atlanta, GA 30339

June 11, 2021

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: David Gessert

**Re: Inhibikase Therapeutics, Inc.  
Registration Statement on Form S-1**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-1 filed on the date hereof (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective on **Tuesday, June 15, 2021, at 5:00 p.m.** (Eastern Time), or as soon thereafter as practicable.

Please feel free to direct any questions or comments concerning this request to Merrill M. Kraines, Esq. of Troutman Pepper Hamilton Sanders LLP at (212) 808-2711.

The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

**INHIBIKASE THERAPEUTICS, INC.**

By: /s/ Milton H. Werner, Ph.D.  
Name: Milton H. Werner, Ph.D.  
Title: President and Chief Executive Officer

cc: Merrill M. Kraines, Esq., Troutman Pepper Hamilton Sanders LLP